Oral prednisolone in the treatment of acute gout: A pragmatic, multicenter, double-blind, randomized trial

Annals of Internal Medicine

Volumn 164, Issue 7, 2016, Pages 464-471

  Rainer, Timothy Hudson ^a   Cheng, Chi Hung ^b   Janssens, Hein J E M ^c   Man, Chi Yin ^d   Tam, Lai Shan ^b   Choi, Yu Fai ^e   Yau, Wah Hon ^f   Lee, Ka Hing ^g   Graham, Colin Alexander ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NORTH DISTRICT HOSPITAL   (Hong Kong)

^e PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^f HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^g UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; PARACETAMOL; PLACEBO; PREDNISOLONE; ANTIINFLAMMATORY AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ACUTE DISEASE; ACUTE GOUT; ADULT; AGED; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EMERGENCY WARD; FEMALE; GOUT; HONG KONG; HUMAN; HYPERTENSION; HYPERURICEMIA; INDIGESTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONARTHRITIS; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; SHORT FORM 36; SOMNOLENCE; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA; CLINICAL TRIAL; EMERGENCY HEALTH SERVICE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PAIN; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; EMERGENCY SERVICE, HOSPITAL; FEMALE; GOUT; HONG KONG; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; PAIN; PREDNISOLONE;

EID: 84962635467     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-2070     Document Type: Article

References (31)

1. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65: 1301-11. [PMID: 16707533]
2. Roddy E, Mallen CD, Doherty M. Gout. BMJ. 2013;347: F5648. [PMID: 24473446] doi: 10.1136/bmj.f5648
3. Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40: 155-75. [PMID: 24703341] doi: 10.1016/j.rdc.2014.01.001
4. Richette P, Bardin T. Gout. Lancet. 2010;375: 318-28. [PMID: 19692116] doi: 10.1016/S0140-6736(09)60883-7
5. Health Grades. Statistics by Country for Gout. 2015. Accessed at www.rightdiagnosis.com/g/gout/stats-country.htm#extrapwarning on 1 June 2014.
6. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65: 1312-24. [PMID: 16707532]
7. Garcia Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal antiinflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3: 98-101. [PMID: 11178116]
8. James DS. The multisystem adverse effects of NSAID therapy. J Am Osteopath Assoc. 1999;99: S1-7. [PMID: 10643174]
9. Bidaut-Russell M, Gabriel SE. Adverse gastrointestinal effects of NSAIDs: Consequences and costs. Best Pract Res Clin Gastroenterol. 2001;15: 739-53. [PMID: 11566038]
10. McGettigan P, Henry D. Current problems with non-specific COX inhibitors. Curr Pharm Des. 2000;6: 1693-724. [PMID: 11102559]
11. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17: 301-4. [PMID: 3314832]
12. Ferrannini E, Pentimone F. Marrow aplasia following colchicine treatment for gouty arthritis. Clin Exp Rheumatol. 1984;2: 173-5. [PMID: 6532622]
13. Roberts WN, Liang MH, Stern SH. Colchicine in acute gout. Reassessment of risks and benefits. JAMA. 1987;257: 1920-2. [PMID: 3820512]
14. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al; British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46: 1372-4. [PMID: 17522099]
15. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: A double-blind, randomized, controlled trial. Ann Emerg Med. 2007; 49: 670-7. [PMID: 17276548]
16. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet. 2008;371: 1854-60. [PMID: 18514729] doi: 10.1016/S0140-6736 (08)60799-0
17. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64: 1447-61. [PMID: 23024029] doi: 10.1002/acr.21773
18. Rainer TH, Graham CA. A significant step forward for gout. Lancet. 2008;371: 1816-8. [PMID: 18514713] doi: 10.1016/S0140 -6736(08)60775-8
19. Sturrock RD. Gout. Easy to misdiagnose [Editorial]. BMJ. 2000; 320: 132-3. [PMID: 10634714]
20. Bennett PH, Wood PHN, eds. Population Studies of the Rheumatic Diseases. Proceedings of the 3rd International Symposium, New York, New York, 5-10 June 1966. Amsterdam, the Netherlands: Excerpta Medica Foundation; 1968: 457-8.
21. Huskisson EC. Measurement of pain. Lancet. 1974;2: 1127-31. [PMID: 4139420]
22. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996;27: 485-9. [PMID: 8604867]
23. Sealed Envelope. Power Calculator for Binary Outcome Equivalence Trial. 2012. Accessed at www.sealedenvelope.com/power/binary-equivalence on 1 June 2014.
24. Schumacher HR. Crystal-induced arthritis: An overview. Am J Med. 1996;100: 46S-52S. [PMID: 8604727]
25. Rott KT, Agudelo CA. Gout. JAMA. 2003;289: 2857-60. [PMID: 12783917]
26. Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: Population based case-control study. BMJ. 2012;344: D8190. [PMID: 22240117] doi: 10.1136/bmj.d8190
27. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH; MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168: 1104-10. [PMID: 18504339] doi: 10.1001/archinte.168.10.1104
28. Krishnan E. Chronic kidney disease and the risk of incident gout among middle-aged men: A seven-year prospective observational study. Arthritis Rheum. 2013;65: 3271-8. [PMID: 23982888] doi: 10.1002/art.38171
29. Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170: 1120-6. [PMID: 20625017] doi: 10.1001/archinternmed.2010.196
30. Kienhorst LB, Janssens HJ, Fransen J, Janssen M. The validation of a diagnostic rule for gout without joint fluid analysis: A prospective study. Rheumatology (Oxford). 2015;54: 609-14. [PMID: 25231179] doi: 10.1093/rheumatology/keu378
31. Dorlo TP, Jager NG, Beijnen JH, Schellens JH. [Concomitant use of proton pump inhibitors and systemic corticosteroids]. Ned Tijdschr Geneeskd. 2013;157: A5540. [PMID: 23657097]